Flickr Albums
Close
25-Sep-15
Novartis' new heart failure medicine Entresto™ (sacubitril valsartan) recommended by CHMP for EU approval
Positive opinion from EU review body puts Entresto (sacubitril valsartan) on track to be approved for HFrEF patients across Europe by the end of 2015
Entresto (sacubitril valsartan) was studied in world's largest heart failure trial, which was stopped early on strength of results that showed a 20% cut in cardiovascular deaths versus the ACE inhibitor, enalapril

Frimley, September 25, 2015 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Entresto™ (sacubitril valsartan). Pending final approval by the European Commission (EC), Entresto (sacubitril valsartan), previously known as LCZ696, will be licensed for use in the UK for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction (HFrEF).

"Despite widespread use of available treatments and implementation of NICE guidelines, outcomes remain poor for those diagnosed with heart failure. The CHMP's endorsement of Entresto brings hope to heart failure patients in the UK," said Hugh O'Dowd, General Manager at Novartis UK & Ireland.

The CHMP's decision, which follows previous US and Swiss approvals, is based on results from the 8,442-patient PARADIGM-HF study in patients with HFrEF, which was stopped early when it was shown Entresto (sacubitril valsartan) significantly reduced the risk of cardiovascular death versus ACE-inhibitor enalapril1. At the end of the study patients who were given Entresto (sacubitril valsartan) were more likely to be alive and less likely to have been hospitalised for heart failure than those given enalapril. Analysis of safety data showed that Entresto (sacubitril valsartan) had a similar tolerability profile to enalapril.

"The striking results in the PARADIGM-HF trial led me to believe that, once approved, LCZ696 could quickly replace what has been the bedrock treatment for more than 20 years, ACE-inhibitors," said Professor John McMurray of the University of Glasgow and one of two Principal Investigators. "Thousands of lives could be extended and hospital admissions prevented with LCZ696's unique ability to boost natriuretic peptides, heart-helpful hormones, while simultaneously inhibiting the RAAS system."

Heart failure is a highly debilitating, life-threatening condition in which the heart cannot pump enough blood around the body because the muscles of the heart become too weak or too stiff to work properly2. As a consequence, patients face a high risk of death, repeated hospitalisations and symptoms such as breathlessness, fatigue and fluid retention that significantly impact quality of life. Heart failure affects around 550,000 people in the UK3 and costs the NHS about £2.3bn a year4. Even though so many people live with heart failure, most fail to recognise the symptoms, meaning many are misdiagnosed or incorrectly attribute the signs to growing older.

Early this month, Entresto (sacubitril valsartan) was given a positive scientific opinion under the Medicines and Healthcare products Regulatory Agency (MHRA) Early Access to Medicines Scheme (EAMS) for patients with significant unmet medical need. This allows Entresto (sacubitril valsartan) to be made available to eligible patients before the EC makes a final European licensing decision based on the recommendations of the CHMP.
High Definition broadcast quality video is available for download.
Standard-Definition broadcast quality video is available for download in PAL & NTSC.
Streaming quality video is available for download as WMV,Quicktime or FLV.
Production quality audio files are available for download.
Production quality print images are available for download.
YouTube videos are also associated with this article.
Flickr images are also associated with this article.

Sorry

This content is no longer available.

It may have expired or been deleted.

Sorry

This content is no longer available.

It may have expired or been deleted.

For More Information
Disclaimer
Novartis has partnered with TheNewsMarket to provide broadcast-standard video - delivered digitally. To make sure that our assets are available to appropriate audiences, some assets appear locked. These are password protected and can only be accessed by journalists and a select group of users. If you are new to the site, please register. Your information will be verified by our team as quickly as possible. Once approved, you will be sent an email confirming your username and password. If you are an existing user of TheNewsMarket, please contact the Novartis media team for access. You may use non-protected material provided in this section for your personal use or for purposes such as news reporting, teaching, scholarship or research. The assets may not be modified and must display a copyright notice in the name of Novartis (Copyright © Novartis).

The information on these pages was factually accurate on the date of publication. This information remains on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates
 
Flickr Albums
Close
This is an RSS feed intended to be viewed in newsreader or syndicated to another site
SUBSCRIBE:
XML